Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reaffirmed a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and increased the price target from $93 to $140, indicating a positive outlook on the company's stock.
January 10, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on Sarepta Therapeutics and raises the price target from $93 to $140, suggesting confidence in the company's prospects.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100